Daqing Wang

Address:

14 Liberty Ln, North Reading, MA 01864

VIN:

2HKYF18537H526224

Make:

HONDA

Model:

PILOT

Year:

2007

US Patent:

7875594, Jan 25, 2011

Filed:

Jan 28, 2008

Appl. No.:

12/020694

Inventors:

Ekambar R. Kandimalla - Southboro MA, US
Sudhir Agrawal - Shrewsbury MA, US
Daqing Wang - Bedford MA, US
Lakshmi Bhagat - Framingham MA, US
Dong Yu - Westboro MA, US

Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A61K 39/395

US Classification:

514 44

Abstract:

The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.

US Patent:

7884197, Feb 8, 2011

Filed:

Dec 12, 2007

Appl. No.:

11/954726

Inventors:

Ekambar Kandimalla - Southboro MA, US
Mallikarjuna Putta - Burlington MA, US
Dong Yu - Westboro MA, US
Lakshmi Bhagat - Framingham MA, US
Daqing Wang - Bedford MA, US
Sudhir Agrawal - Shrewsbury MA, US

Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07H 21/02
C07H 21/04
C12Q 1/68
C12N 5/00
C12N 5/02
A61K 49/00
A61K 31/70
A01N 43/04

US Classification:

536 231, 435 6, 435375, 424 92, 514 44 R

Abstract:

The invention provides novel oligonucleotide-based compounds that individually provide distinct immune response profiles through their interactions as agonists with TLR9. The TLR9 agonists according to the invention are characterized by specific and unique chemical modifications, which provide their distinctive immune response activation profiles.

US Patent:

7960362, Jun 14, 2011

Filed:

Jul 31, 2008

Appl. No.:

12/183439

Inventors:

Ekambar Kandimalla - Southboro MA, US
Mallikarjuna Putta - Burlington MA, US
Daqing Wang - Bedford MA, US
Dong Yu - Westboro MA, US
Lakshmi Bhagat - Framingham MA, US
Sudhir Agrawal - Shrewsbury MA, US

Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA

International Classification:

A01N 43/04
A61K 39/00
A61K 45/00
C07H 21/02

US Classification:

514 44, 4241841, 4242781, 514 11, 536 231

Abstract:

The invention relates to synthetic chemical compositions that are useful for modulation of Toll-Like Receptor (TLR)-mediated immune responses. In particular, the invention relates to agonists of Toll-Like Receptor 9 (TLR9) that generate unique cytokine and chemokine profiles.

US Patent:

8106173, Jan 31, 2012

Filed:

Apr 6, 2007

Appl. No.:

11/697422

Inventors:

Ekambar R. Kandimalla - Southboro MA, US
Tao Lan - Arlington MA, US
Yukui Li - Newton MA, US
Dong Yu - Westboro MA, US
Daqing Wang - Bedford MA, US
Mallikarjuna Reddy Putta - Burlington MA, US
Sudhir Agrawal - Shrewsbury MA, US

Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07H 21/02
A61K 48/00

US Classification:

536 231, 514 44 R

Abstract:

The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.

US Patent:

8153605, Apr 10, 2012

Filed:

Aug 4, 2009

Appl. No.:

12/534911

Inventors:

Ekambar Kandimalla - Southboro MA, US
Mallikarjuna Putta - Burlington MA, US
Lakshmi Bhagat - Framingham MA, US
Daqing Wang - Bedford MA, US
Dong Yu - Westboro MA, US
Sudhir Agrawal - Shrewsbury MA, US

Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C12N 15/11
C12Q 1/68
C07H 21/04

US Classification:

514 44A, 435 61, 536 231, 536 245

Abstract:

Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR3. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR3 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR3 expression and for prevention or treatment of diseases wherein modulation of TLR3 expression would be beneficial are provided.

US Patent:

8153777, Apr 10, 2012

Filed:

Nov 4, 2009

Appl. No.:

12/612413

Inventors:

Ekambar Kandimalla - Southboro MA, US
Mallikarjuna Putta - Burlington MA, US
Lakshmi Bhagat - Framingham MA, US
Daqing Wang - Bedford MA, US
Dong Yu - Westboro MA, US
Sudhir Agrawal - Shrewsbury MA, US

Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07H 21/04
C07H 21/02
A61K 48/00
A61K 39/395
C12N 15/63

US Classification:

536 245, 536 231, 536 2431, 536 2433, 514 44, 4241301, 4353201

Abstract:

Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR5. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR5 expression and for prevention or treatment of diseases wherein modulation of TLR5 expression would be beneficial are provided.

US Patent:

8188261, May 29, 2012

Filed:

Jul 7, 2008

Appl. No.:

12/168641

Inventors:

Ekambar Kandimalla - Southboro MA, US
Tao Lan - Arlington MA, US
Daqing Wang - Bedford MA, US
Lakshmi Bhagat - Framingham MA, US
Sudhir Agrawal - Shrewsbury MA, US

Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07H 21/04

US Classification:

536 245, 536 2431, 536 241, 514 44

Abstract:

The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.

US Patent:

8202974, Jun 19, 2012

Filed:

Feb 10, 2010

Appl. No.:

12/703612

Inventors:

Tao Lan - Arlington MA, US
Ekambar Kandimalla - Southboro MA, US
Daqing Wang - Bedford MA, US
Sudhir Agrawal - Shrewsbury MA, US

Assignee:

Idera Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07H 21/02
C07H 21/04
C12Q 1/68
C12N 5/00
C12N 5/02
A61K 49/00
A61K 31/70
A01N 43/04

US Classification:

536 231, 435 61, 435375, 424 92, 514 44 R

Abstract:

The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA-based oligoribonucleotides with improved nuclease and RNase stability and that selectively induce immune modulatory activity through TLR7.